AEAnna S. Esenina

Anna S. Esenina

*This is an algorithmically generated author record based on publicly available information.

Anna S. Esenina has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development and validation of a method for the quantitative determination of succinate in rat blood plasma by HPLC-MS/MS

    by P. Yu. Mylnikov, A. S. Esenina, I. V. Chernykh, A. S. Polupanov, A. V. Shchulkin, E. N. Yakusheva, П. Ю. Мыльников, А. С. Есенина, И. В. Черных, А. С. Полупанов, et al.

    Relevance. Succinate is a central metabolite of the Krebs cycle and also a regulator of numerous processes via the specific succinate receptor SUCNR1. Succinate is an important component of several pharmacological preparations. However, its pharmacokinetics following the administration of these substances remain poorly understood. A sensitive analytical method is required to perform such studies. Objective. To develop and validate a method for the quantitative determination of succinate in rat blood plasma. Methods. The analysis was performed using HPLC-MS/MS — an Ultimate 3000 TSQ Fortis system and a UCT Selectra C18 column (4.6 mm × 100 mm, 3 µm, 100 Å). The separation temperature was 35 °C, and the flow rate was 0.5 mL/min. A gradient elution mode was used with a mixture of 0.1 % aqueous formic acid and 0.1 % formic acid in methanol. The injection volume was 5 µL. For sample preparation, methanol containing chloramphenicol at a concentration of 10 ng/mL as an internal standard was used. A model matrix was used during validation. For succinate detection, the following mass transitions were used in negative ionization mode: 117 m/z → 98.7 m/z, 117 m/z → 73.1 m/z. Results. The method demonstrated selectivity, sensitivity, accuracy, precision, and linearity in the concentration range of 200–20,000 ng/mL. No carryover or matrix effect was observed. The recovery rate was over 96 %. Succinate was stable under the employed storage conditions. Conclusion. A method for the quantitative determination of succinate in rat blood plasma has been developed and validated. This method can be used to analyze endogenous succinate concentrations and the pharmacokinetics of succinate following the administration of succinate-containing drugs.

  • Open Access

    Cells of the Caco-2 line as a model for studying the absorption of medicinal substances

    by A. V. Shchulkin, Yu. S. Tranova, Yu. V. Abalenikhina, A. S. Esenina, A. A. Slepnev, E. N. Yakusheva, Ю. В. Абаленихина

    Cells of the Caco-2 line have the basic properties of enterocytes of the small intestine, and therefore can be used to study the absorption of medicinal substances. Aim. To characterize the properties of the Caco-2 cell line from the Institute of Cytology of the Russian Academy of Sciences and to evaluate with its help the mechanism of absorption of the original domestic drug - ethylmethylhydroxypyridine succinate (EMGPS). Materials and methods. The study was performed on Caco2 cells that were cultured for 21 days, since at this time their spontaneous differentiation into polarized cells similar to enterocytes of the small intestine occurs. The density of the cell monolayer was estimated by the value of transepithelial resistance. The number of major efflux proteins of glycoprotein-P transporters (Pgp) and breast cancer resistance protein (BCRP) in Caco-2 cells was analyzed using enzyme immunoassay. In specialized transwell systems, the transport of the Pgp substrate fexofenadine (40, 150 and 300 microns), the BCRP substrate methotrexate (5, 10, 50 microns) and EMGPS (10, 100 and 250 microns) through the cell monolayer was studied. The results of the study. By day 21 of cultivation, cells of the Caco2 line formed a merging monolayer with pronounced dense contacts. The amount of Pgp and BCRP was 110.8±14.1 ng/mg and 4.39±0.12 ng/mg, respectively, which correlates with the amount of these proteins in the human small intestine. Transport of fexofenadine (40, 150 and 300 microns) and methotrexate (5 microns) from the basolateral chamber to the apical chamber (corresponding to transport from enterocytes to the intestinal lumen) prevailed over transport in the opposite direction, which is associated with the work of Pgp and BCRP. The transport of EMGPS significantly exceeded the transport of fexofenadine and methotrexate and was symmetrical with respect to the cellular monolayer. Conclusion. Thus, the cells of the Caco-2 line, commercially available in the Russian Federation, have the basic properties of enterocytes of the small intestine, and can be used to study the absorption of medicinal substances in vitro. EMGPS quickly passes through the cellular monolayer, and the mechanism of its absorption is passive diffusion, without the participation of specific transporters.


  • Open Access

    Role of P-glycoprotein in the pharmacotherapy of pregnant women

    by N. M. Popova, A. V. Shchulkin, I. V. Chernykh, A. S. Esenina, M. M. Gradinar, E. N. Yakusheva

    This review addresses the function of the protein-transporter glycoprotein-P (Pgp, ABCB1 protein) and the expression of its encoding gene MDR1/mdr1 throughout the gestational period in humans and animals. We discuss the relationship between the transporter function and the hormone fluctuations during pregnancy. We cite studies on the association between the MDR1/mdr1 gene polymorphisms and the hemato-placental barrier permeability for Pgp substrates, as well as fetal malformations. Under a separate section, drugs commonly used in pregnant women are characterized in terms of their roles as substrates, inducers or inhibitors of the Pgp transporter.

  • Open Access

    P-glycoprotein functional activity in «soviet chinchilla» rabbits during pregnancy

    by Natalia M. Popova, Aleksey V. Shchulkin, Ivan V. Chernykh, Anna S. Esenina, Maria M. Gradinar, Larisa V. Nikiforova, Alexander N. Ryabkov, Elena N. Yakusheva, Шулькин Алексей Владимирович, Рябков Александр Николаевич

    P-glycoprotein (Pgp, ABCB1-protein) is a membrane transporter protein that plays the key role in pharmacokinetics of drugs with a broad spectrum of action. Substrates of this transporter are some medical drugs (antibacterial, antiretroviral, hypotensive) that are prescribed to pregnant women for long-term intake, sometimes throughout the whole gestation period. Aim to study the activity of Pgp on the organism level in rabbits of Soviet Chinchilla breed in pregnancy. Materials and Methods. The study was performed on 21 Soviet Chinchilla female rabbits (3000-3500 g). The animals were divided into 3 series. The first series (n=6) included rabbits with 7 days of pregnancy; the second series (n=5) - animals with 14 days of pregnancy; the third series (n=10) - rabbits with 21 days of pregnancy. 7 Days before the study and in the indicated gestation periods, functional activity of Pgp was assessed by the pharmacokinetics of marker transporter substrate – fexofenadine, after its single oral introduction (67.5 mg/kg). Besides, serum concentrations of progesterone, estradiol, testosterone and prolactin were determined by radio immune method Results. In all the studied gestational periods, serum concentrations of estradiol, testosterone and prolactin did not significantly differ from those before pregnancy, but the level of progesterone in blood serum was significantly elevated above the norm. On the 7th day of pregnancy pharmacokinetic parameters of fexofenadine did not show any reliable changes as compared to the initial va-lues. On the 14th day of pregnancy a reliable increase in Cmax, AUC0-t, T1/2 of fexofenadine was noted as compared to the parameters before pregnancy, which indicates a decrease in Pgp functional activity on the organism level. On the 21st day of pregnancy Cmax of fexofenadine remained elevated. Other pharmacokinetic parameters of fexofenadine did not show reliable changes. Conclusion. Reduction in Pgp functional activity, determined by the pharmacokinetics of its marker substrate (fexofenadine), was noted in rabbits of Soviet Chinchilla breed on the 14th and 21st days of pregnancy with the underlying significant increase in progesterone level.